Clinical use of Bevacizumab in treating refractory glaucoma.
Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab found its way into ophthalmology and clinical practice all around the world. The objective of this review is to present the ophthalmic dosage and administration pathways of bevacizumab in treating refractory glaucoma patients.


BACKGROUND
VEGF = vascular endothelial growth factor, FDA = Food and Drug Administration, AMD = age-related macular degeneration.
Anatomy Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
V
V
Popescu
Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania.
S
S
Pricopie
Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania ; Ophthalmology Department, Regina Maria - private health care network, Bucharest, Romania.
M
M
Totir
Ophthalmology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
R
R
Iancu
Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania.
S
S
Yasyn
Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania.
C
C
Alexandrescu
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans
D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
bevacizumab; glaucoma; trabeculectomy; vascular endothelial growth factor